Disponible solo en inglés.
Resumen del programa nacional del corpus xOH. Comprueba siempre la fuente oficial vigente.
Single dose. 75-79 routine since Sept 2024. From 1 April 2026: expanded to ≥80 with NO upper age limit + all residents in care homes for older adults (regardless of age). Co-administration with COVID-19 spring 2026 campaign permitted.
Single dose from 28 weeks gestation in every pregnancy (protects infant via transplacental antibody).
2 doses Shingrix (0, then 2-6 months; up to 12 months). Phased age expansion (65 and 70 cohorts) toward routine 60-80 over time. Replaced Zostavax (live) — Shingrix non-live.
Severely immunosuppressed adults 18+ eligible for Shingrix (non-live, safe in immunosuppression unlike old Zostavax).
Single dose PPV23 at 65 (one-off, not routinely repeated). Transition to PCV20 underway as PPV23 stock is exhausted.
At-risk groups: PPV23 (revaccination every 5 years only for asplenia/CKD/immunosuppressed). Occupational: welders + metal-fume exposure now an at-risk indication (JCVI).
Annual inactivated influenza vaccine (aQIV adjuvanted or cell-based preferred 65+).
Annual flu vaccine for pregnant women (any stage), clinical risk groups, carers, and frontline health/social care workers (occupational — employer-provided).
Seasonal boosters per JCVI advice each campaign (cohorts vary by season — typically 75+, immunosuppressed, older-adult care home residents). NOT universal.
Single dose from 16 weeks gestation (ideally before 32 weeks) every pregnancy — infant protection. NOTE: pregnancy is the main UK adult pertussis indication (no routine non-pregnant adult Tdap).
UK uses Td/IPV (Revaxis) for adult boosters — NOT US-style Tdap. 5 doses confer lifelong protection. Boosters for tetanus-prone wounds or incomplete history; teenage booster at 14 (school Year 9).
2 doses (≥1 month apart) for any adult without documented 2 doses or immunity. Occupational priority: healthcare/laboratory + education staff. UK measles resurgence — active catch-up.
SINGLE dose (UK moved from 2 doses to 1 dose, Sept 2023) for immunocompetent under 25. Routine school Year 8 (12-13); catch-up to 25th birthday if eligible and missed.
MSM up to 45 offered HPV via sexual health/GUM services (immunocompetent: doses per current guidance; immunocompromised/HIV: 3 doses).
Occupational HBV programme for HCW/lab/exposure-prone procedures: 3-dose (0,1,6) or accelerated; post-vaccination anti-HBs check (≥10 mIU/mL adequate). Employer-provided under COSHH.
At-risk: sewage workers, lab staff handling HAV, travellers to endemic areas, MSM, PWID, chronic liver disease.
New university entrants <25 (freshers); asplenia/complement disorders; travel to meningitis belt/Hajj (Saudi visa requirement).
At-risk only in adults: asplenia, complement deficiency, complement-inhibitor therapy, and laboratory staff who handle Neisseria meningitidis.
2 doses for non-immune (seronegative) healthcare workers + non-immune close contacts of immunocompromised patients. Live vaccine — contraindicated in pregnancy/immunosuppression.
UK offers occupational BCG to unvaccinated, tuberculin-negative HCW/lab staff with potential TB exposure (NOT routine in US). Single intradermal dose.
DHSC (UK) / NHS England / Scotland / Wales / NI — uk-imm-green-book · 2026
Última revisión: 2026-06-03
Abrir en la web completaHerramienta de apoyo: no sustituye el juicio clínico.
xOH es una herramienta informativa de apoyo para profesionales sanitarios. No es un producto sanitario certificado (Reglamento UE 2017/745) y no sustituye el juicio clínico.